Vaxcyte, Inc. (PCVX) financial statements and ratios from SEC XBRL: revenue $119.72M (TTM), net margin -640.4%, revenue growth 8.8% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $119.72M |
| Net Margin | -640.4% |
| Revenue Growth (YoY) | 8.8% |
| EPS Growth (YoY) | 48.2% |
| FCF Growth (YoY) | 40.9% |
| Price / Book | 2.96 |
| Price / Sales | 73.87 |
| FCF Yield | -13.4% |
| Altman Z-Score | 15.28 (safe) |
| Sector P/E (Healthcare) | 21.6 |
PCVX overview · PCVX earnings · PCVX KPIs · PCVX investor relations · PCVX ownership · PCVX peers · PCVX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.